PanCO: An open-label, single-arm pilot study of phosphorus-32 (P-32; Oncosil) microparticles in patients with unresectable locally advanced pancreatic adenocarcinoma (LAPC) in combination with FOLFIRINOX or gemcitabine plus nab-paclitaxel (GNP) chemotherapies.

Paul J Ross; Daniel Croagh; Morteza Aghmesheh; Adnan Nagrial; Nguyen Nam; Mehrdad Nikfarjam; Harpreet Singh Wasan; Thankamma V Ajithkumar; Chinenye Iwuji; Alain Hendlisz; Thomas Maher; Anna Kraszewski; Marion Harris

Conference Proceedings

PanCO: An open-label, single-arm pilot study of phosphorus-32 (P-32; Oncosil) microparticles in patients with unresectable locally advanced pancreatic adenocarcinoma (LAPC) in combination with FOLFIRINOX or gemcitabine plus nab-paclitaxel (GNP) chemotherapies.

Paul J Ross, Daniel Croagh, Morteza Aghmesheh, Adnan Nagrial, Nguyen Nam, Mehrdad Nikfarjam, Harpreet Singh Wasan, Thankamma V Ajithkumar, Chinenye Iwuji, Alain Hendlisz, Thomas Maher, Anna Kraszewski, Marion Harris

JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2019

DOI: 10.1200/JCO.2019.37.15_suppl.4125

Abstract

4125 Background: LAPC is associated with a poor prognosis. Current standard treatment is limited to chemotherapy or chemo-radiotherapy. P-32 Microparticles is a brachytherapy device that implants a predetermined dose of P-32 into pancreatic tumours via endoscopic ultrasound (EUS) guidance. This reports the initial results of a pilot study in combination with chemotherapy. Methods: Eligible patients were permitted to receive either GNP or FOLFIRINOX. P-32 was implanted at week 4 or 5. The dose of P-32 was calculated from tumour volume to deliver an absorbed dose of 100 Gy. Diffusion pattern of the P-32 suspension was assessed by EUS and bremsstrahlung SPECT/CT imaging. Safety data was graded..

View full abstract